Narodna in univerzitetna knjižnica, Ljubljana (NUK)
Naročanje gradiva za izposojo na dom
Naročanje gradiva za izposojo v čitalnice
Naročanje kopij člankov
Urnik dostave gradiva z oznako DS v signaturi
  • Ocena učinkovitosti prvega zdravljenja z bortezomibom pred avtologno presaditvijo krvotvornih matičnih celic pri diseminiranem plazmocitomu = Effectiveness of first treatment with bortezomib prior to autologous stem cell transplantation for multiple myeloma
    Černelč, Peter ; Kodre, Veronika
    Background: In this retrospective study we evaluated effectiveness and safety of first- line treatment with bortezomib and dexamethasone in multiple myelomapatients, comparing our results with ... already published clinical studies. Methods: Patients received bortezomib as part of everyday clinical practice and according to the latest guidelines of the Združenje hematologov Slovenije . Patients who were previously treated with first-line VAD (vincristine, doxorubicin modified with farmarubicine, dexamethasone), but dueto uneffectiveness changed the treatment to bortezomib, were also included in the study. In 30 patients effectivenes was evaluated after average 3-4 cycles of bortezomib and dexamethasone according to the modified Southwest Oncology Group criteria. Treatment effectiveness was evaluated according to the previous VAD treatment, renal function and cytogenetic analysis. Side effects and reasons for early treatment discontinuation were described. Results: Patients received 2 to 8 cycles (median 4 cycles) of bortezomib and dexamethasone treatment. After average 3-4 cycles, 80% of patients acheived good treatment response (56.7% very good partial response, 23.3% partial response). We observed that the treatment, renal insufficiency and negative cytogenetic analysis, sionce we observed similar rates of very good partial response ande partial response in patients without previous VAD treatment (82.3% vs. 76.9%), normal renal function (85.7% vs. 75%) and normal cytogenetics (77.8% vs. 80%), although statistical evaluation was not possibledue to small number of patients. The most common side effect was neuropathy (40%) and in 5 patients (16.6%), due to grade 3 or more, the treatment was discontinued. Other side effects were: anemia (26%), infection (166%), thrombocytopenia (10%), neutropenia (6.6%), gastrointestinal problems (23.3%) and herpes zooster (6.6%). (Abstract truncated at 2000 characters).
    Vir: Zdravniški vestnik : glasilo Slovenskega zdravniškega društva = Slovenian medical journal = journal of Slovenian Medical Association. - ISSN 1318-0347 (Letn. 81, št. 4, apr. 2012, str. 304-311)
    Vrsta gradiva - članek, sestavni del
    Leto - 2012
    Jezik - slovenski
    COBISS.SI-ID - 29870041

    Povezava(-e):

    http://www.szd.si/user_files/vsebina/Zdravniski_Vestnik/2012/april/304-11.pdf
    Digitalna knjižnica Slovenije - dLib.si

Vnos na polico